Phase I-II evaluation of XXXX in adults with @entity3052 .

@entity1 @entity632 @entity981 @entity712 @entity66 @entity5699 @entity33 @entity3052 @entity1209 @entity299 @entity17597
Twenty courses of @entity17597 were administered to 18 evaluable adult @entity1 with @entity3052 (14 @entity3052 , 2 @entity981 , 2 CGL-BC). All but one received daily doses of 6-14 mg/m2 for 5 consecutive days. Two @entity1 older than 60 yr had not prior chemotherapy and the others had refractory or @entity66 . The median age was 60 yr. Three @entity3052 @entity1 achieved complete remission for 8, 9 and 9 months respectively, with no maintenance therapy. None of these had proven clinical resistance to @entity5699 and/or @entity632 . @entity33 was dose-related and dose-limiting. @entity1209 were rare. Alopecia was constant. @entity299 was ascribed to @entity17597 in two @entity1 . One episode of @entity712 seemed clearly drug-related and recovered with symptomatic treatment. In conclusion, encouraging antileukemic activity was observed with @entity17597 in poor-risk @entity1 . At doses up to 12 mg/m2 day X 5, extramedullary toxicity remained acceptable.
